Avalanche AAVL Securities Lawsuit

Company:	Avalanche
Ticker Symbol:	AAVL
Class Period:	Jul-31-14 to Jun-15-15
Date Filed:	Jun-10-15
Lead Plaintiff Deadline:	Aug-9-15
Court:	Northern District of California
Allegations:

New York, NY: A securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Avalanche Biotechnologies ("Avalanche"or the "Company") (NASDAQ: AAVL), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between July 31, 2014 and June 15, 2015, inclusive (the "Class Period.) The class in this case has not yet been certified.

Avalanche is a biotechnology company engaged in the development of gene therapies for patients with various ophthalmic diseases. According to the complaint, on June 15, 2015, Avalanche held a conference call to discuss their Phase IIa trial results concerning a gene therapy treatment for wet age-related macular degeneration. During the call Avalanche stated that the study was not designed to demonstrate statistically significant differences between the active and control groups. As a result, shares dropped over 56% the following day to end at $17.05 on June 16, 2015.



If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Avalanche AAVL Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Avalanche securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.